Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells - PubMed (original) (raw)
Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells
O Hjertner et al. Br J Haematol. 2000 Jun.
Free article
Abstract
Binding of urokinase (uPA) to its receptor (uPAR; CD87) focuses proteolytic activity on the cell surface and this system is of importance in malignant matrix degradation and tumour invasion. By immunocytochemistry and flow cytometry, we found that primary myeloma cells and myeloma cell lines expressed uPA and uPAR. Soluble uPA was present in cell line supernatants and lysates in low concentrations. In cell lines, uPA and uPAR were located both on the cell surface and intracellularly, but the expression of both proteins was low. Higher levels of uPAR was detected on the cell surface of primary myeloma cells. When primary myeloma cells were gated by CD45 expression, stronger expression was found on immature CD45+ cells than on mature CD45-/dim cells. Finally, both myeloma cell lines and primary cells were able to cleave a uPA-specific substrate showing that the uPA system is functionally active. We conclude that myeloma cells are able to produce uPA and uPAR. This opens up a possible role of the uPA system in myeloma cell invasion and in the proteolytic digestion of bone matrix.
Similar articles
- Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Costantini V, Sidoni A, Deveglia R, Cazzato OA, Bellezza G, Ferri I, Bucciarelli E, Nenci GG. Costantini V, et al. Cancer. 1996 Mar 15;77(6):1079-88. doi: 10.1002/(sici)1097-0142(19960315)77:6<1079::aid-cncr12>3.0.co;2-z. Cancer. 1996. PMID: 8635127 - In vitro anti-proliferative and anti-invasive role of aminoterminal fragment of urokinase-type plasminogen activator on 8701-BC breast cancer cells.
Luparello C, Del Rosso M. Luparello C, et al. Eur J Cancer. 1996 Apr;32A(4):702-7. doi: 10.1016/0959-8049(95)00657-5. Eur J Cancer. 1996. PMID: 8695276 - Analysis of expressions of components in the plasminogen activator system in high- and low-metastatic human lung cancer cells.
He C, He P, Liu LP, Zhu YS. He C, et al. J Cancer Res Clin Oncol. 2001;127(3):180-6. doi: 10.1007/s004320000192. J Cancer Res Clin Oncol. 2001. PMID: 11260863 - Regulation and role of urokinase plasminogen activator in vascular remodelling.
Tkachuk V, Stepanova V, Little PJ, Bobik A. Tkachuk V, et al. Clin Exp Pharmacol Physiol. 1996 Sep;23(9):759-65. doi: 10.1111/j.1440-1681.1996.tb01177.x. Clin Exp Pharmacol Physiol. 1996. PMID: 8911711 Review. - Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T, Behrendt N, Ploug M. Plesner T, et al. Stem Cells. 1997;15(6):398-408. doi: 10.1002/stem.150398. Stem Cells. 1997. PMID: 9402652 Review.
Cited by
- Augmented expression of urokinase plasminogen activator and extracellular matrix proteins associates with multiple myeloma progression.
Khan R, Gupta N, Kumar R, Sharma M, Kumar L, Sharma A. Khan R, et al. Clin Exp Metastasis. 2014 Jun;31(5):585-93. doi: 10.1007/s10585-014-9652-7. Epub 2014 May 8. Clin Exp Metastasis. 2014. PMID: 24807734 - Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic.
Mazar AP, Ahn RW, O'Halloran TV. Mazar AP, et al. Curr Pharm Des. 2011;17(19):1970-8. doi: 10.2174/138161211796718152. Curr Pharm Des. 2011. PMID: 21711234 Free PMC article. - Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma.
Asosingh K, Menu E, Van Valckenborgh E, Vande Broek I, Van Riet I, Van Camp B, Vanderkerken K. Asosingh K, et al. Clin Exp Metastasis. 2002;19(7):583-91. doi: 10.1023/a:1020987830132. Clin Exp Metastasis. 2002. PMID: 12498387 - Macrophages and Urokinase Plasminogen Activator Receptor System in Multiple Myeloma: Case Series and Literature Review.
Manzo P, Giudice V, Napolitano F, De Novellis D, Serio B, Moscato P, Montuori N, Selleri C. Manzo P, et al. Int J Mol Sci. 2023 Jun 23;24(13):10519. doi: 10.3390/ijms241310519. Int J Mol Sci. 2023. PMID: 37445697 Free PMC article. Review. - Hypermethylation of the Promoter Region of miR-23 Enhances the Metastasis and Proliferation of Multiple Myeloma Cells via the Aberrant Expression of uPA.
Ran Q, Xu D, Wang Q, Wang D. Ran Q, et al. Front Oncol. 2022 May 30;12:835299. doi: 10.3389/fonc.2022.835299. eCollection 2022. Front Oncol. 2022. PMID: 35707350 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous